BRPI0317276B8 - método para a preparação de partículas de replicon de alfavírus (arps) - Google Patents

método para a preparação de partículas de replicon de alfavírus (arps)

Info

Publication number
BRPI0317276B8
BRPI0317276B8 BRPI0317276A BR0317276A BRPI0317276B8 BR PI0317276 B8 BRPI0317276 B8 BR PI0317276B8 BR PI0317276 A BRPI0317276 A BR PI0317276A BR 0317276 A BR0317276 A BR 0317276A BR PI0317276 B8 BRPI0317276 B8 BR PI0317276B8
Authority
BR
Brazil
Prior art keywords
particles
alphavirus replicon
replicon particles
chloride
alphavirus
Prior art date
Application number
BRPI0317276A
Other languages
English (en)
Other versions
BRPI0317276B1 (pt
BR0317276A (pt
Inventor
Alterson Harold
Rayner Jon
F Smith Jonathan
Butler Alterson Kim
Kamrud Kurt
F Maughan Maureen
Dryga Sergey
Original Assignee
Alphavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphavax Inc filed Critical Alphavax Inc
Publication of BR0317276A publication Critical patent/BR0317276A/pt
Publication of BRPI0317276B1 publication Critical patent/BRPI0317276B1/pt
Publication of BRPI0317276B8 publication Critical patent/BRPI0317276B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering

Abstract

partículas de alfavírus e métodos para preparação. a presente invenção refere-se a métodos para a produção de partículas de replicon do alfavírus em altos rendimentos; os rnas do replicon são submetidos à eletroporação em células permissivas, em que as células estão em uma densidade relativamente alta, junto com pelo menos um ácido nucléico auxiliador que fornece as funções necessárias para o empacotamento. após um período de crescimento no meio apropriado, as partículas de replicon do alfavírus são coletadas das superfícies das células em que foram produzidas utilizando uma lavagem com sal em que a concentração de sais é de aproximadamente 0,2 até aproximadamente 5 m de cloreto de sódio, cloreto de cálcio, cloreto de magnésio, cloreto de potássio, acetato de amônio, bicarbonato de amônio, entre outros. após a diluição, se necessário, as partículas podem ser purificadas através de uma técnica cromatográfica adequada.
BRPI0317276A 2002-12-13 2003-12-12 método para a preparação de partículas de replicon de alfavírus (arps) BRPI0317276B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43305802P 2002-12-13 2002-12-13
US60/433,058 2002-12-13
PCT/US2003/039725 WO2004055167A2 (en) 2002-12-13 2003-12-12 Alphavirus particles and methods for preparation

Publications (3)

Publication Number Publication Date
BR0317276A BR0317276A (pt) 2005-11-08
BRPI0317276B1 BRPI0317276B1 (pt) 2020-09-15
BRPI0317276B8 true BRPI0317276B8 (pt) 2021-05-25

Family

ID=32595112

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019005271-9A BR122019005271B1 (pt) 2002-12-13 2003-12-12 método para a preparação de partículas de replicon de alfavírus (arps)
BRPI0317276A BRPI0317276B8 (pt) 2002-12-13 2003-12-12 método para a preparação de partículas de replicon de alfavírus (arps)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019005271-9A BR122019005271B1 (pt) 2002-12-13 2003-12-12 método para a preparação de partículas de replicon de alfavírus (arps)

Country Status (13)

Country Link
US (1) US7078218B2 (pt)
EP (3) EP1590451B1 (pt)
JP (2) JP5079981B2 (pt)
AU (1) AU2003297041B2 (pt)
BR (2) BR122019005271B1 (pt)
CA (2) CA2807515C (pt)
DK (3) DK1590451T3 (pt)
ES (3) ES2552687T3 (pt)
HK (1) HK1082524A1 (pt)
IL (1) IL169076A (pt)
NZ (1) NZ540657A (pt)
WO (1) WO2004055167A2 (pt)
ZA (1) ZA200505517B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
DE60233061D1 (de) * 2001-09-06 2009-09-03 Alphavax Inc Alphavirus replikon-vektorsysteme
ES2618309T3 (es) * 2002-12-13 2017-06-21 Alphavax, Inc. Partículas de replicón de alfavirus multi-antigénico y métodos
NZ540657A (en) 2002-12-13 2006-09-29 Alphavax Inc High-yielding, GMP-compatible, commercially feasible process for producing highly purified alphavirus replicon particle (ARP) preparations for use in human and veterinary medicine
KR101454842B1 (ko) * 2003-03-20 2014-11-04 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
AU2004257214B2 (en) 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US20050266550A1 (en) * 2004-05-18 2005-12-01 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
CA2572921C (en) * 2004-07-09 2017-01-03 The University Of North Carolina At Chapel Hill Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants
NZ555118A (en) * 2004-11-11 2009-09-25 Solvay Biologicals Bv Defective influenza virus particles incapable of producing functional polymerase
CA2597921A1 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
EP1907537A4 (en) * 2005-07-14 2010-11-10 Mayo Foundation PREPARATIONS BASED ON PARAMYXOVIRIDAE VIRUS
US20100233209A1 (en) * 2005-08-11 2010-09-16 Higgs Stephen T Chikungunya virus infectious clones and uses therefor
US8357114B2 (en) * 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
EP2066346B1 (en) 2006-09-12 2019-07-03 AlphaVax, Inc. Alphavirus replicon particles encoding il-12 as immunological adjuvants
US20090022760A1 (en) * 2006-09-12 2009-01-22 Alphavax Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
NZ576563A (en) * 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
WO2008156829A2 (en) 2007-06-21 2008-12-24 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
US20090162395A1 (en) * 2007-09-26 2009-06-25 Crowe Jr James E Vaccine for rsv and mpv
KR101589511B1 (ko) * 2008-04-04 2016-02-01 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 치쿤구니야 바이러스 단백질의 공통 서열, 이를 인코딩하는 핵산 분자, 조성물 및 이를 이용하는 방법
US20100040650A1 (en) * 2008-05-30 2010-02-18 Crowe Jr James E Virus-Like paramyxovirus particles and vaccines
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
ES2525707T3 (es) 2008-12-01 2014-12-29 Alphavax, Inc. Uso de microRNAs para el control de ácidos nucleicos colaboradores de virus
US20120128714A1 (en) 2009-04-08 2012-05-24 Wolchok Jedd D Alphavirus Replicon Particles Expressing TRP2
WO2012001196A2 (es) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos
PL2852671T3 (pl) 2012-05-21 2019-06-28 The Regents Of The University Of California Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
WO2018208856A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
BR112020012190A8 (pt) 2017-12-20 2023-04-11 Vlp Therapeutics Llc Partícula de replicon de alfavírus
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
TW202110870A (zh) 2019-05-30 2021-03-16 美商葛利史東腫瘤科技公司 經修飾之腺病毒
EP4085130A4 (en) 2019-12-31 2024-04-10 Elixirgen Therapeutics Inc TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
US20230366001A1 (en) 2022-05-12 2023-11-16 SunVax mRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
WO2023243679A1 (ja) * 2022-06-17 2023-12-21 学校法人日本医科大学 高力価ウイルスベクターの製造方法
CN115948351B (zh) * 2022-12-01 2023-11-14 杭州养生堂生物医药有限公司 一种分离纯化cvb1的方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5091205A (en) 1989-01-17 1992-02-25 Union Carbide Chemicals & Plastics Technology Corporation Hydrophilic lubricious coatings
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6770283B1 (en) 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
AU6172194A (en) 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
US20020102273A1 (en) 1995-08-08 2002-08-01 Robert B. Grieve Use of alphavirus expression vectors to produce parasite anitgens
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5755770A (en) 1995-01-31 1998-05-26 Boston Scientific Corporatiion Endovascular aortic graft
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5639650A (en) 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
US5827658A (en) 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5824046A (en) 1996-09-27 1998-10-20 Scimed Life Systems, Inc. Covered stent
US5726022A (en) 1996-11-18 1998-03-10 Lifespan Biosciences, Inc. Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5958738A (en) 1997-03-24 1999-09-28 Roche Diagnostics Corporation Procedure for subtractive hybridization and difference analysis
US6261570B1 (en) 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
GB9716611D0 (en) * 1997-08-07 1997-10-08 Cantab Pharmaceuticals Res Ltd Virus preparations and methods
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6197502B1 (en) 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
FI106618B (fi) 1998-03-30 2001-03-15 Sandvik Tamrock Oy Sovitelma painenestekäyttöisen iskulaitteen, kuten esimerkiksi rikotuslaitteen yhteydessä
AU754320B2 (en) * 1998-04-08 2002-11-14 University Of North Carolina At Chapel Hill, The Methods and modified cells for the treatment of cancer
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
DE69937890D1 (de) 1998-07-10 2008-02-14 U S Army Medical Res Inst Of I Impfstoffe gegen neurotoxine von clostridium botulinum
JP2002526421A (ja) 1998-10-05 2002-08-20 ジェンザイム・コーポレーション 癌細胞に差別的に発現する癌ワクチン設計のための遺伝子
US6329201B1 (en) 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
AU2220800A (en) 1998-12-31 2000-07-31 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
JP4637368B2 (ja) 1999-04-14 2011-02-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アルファウイルスに基づくベクター系を利用する免疫応答を生成するための組成物および方法
CA2373970C (en) 1999-07-02 2008-12-30 Endotex Interventional Systems, Inc. Flexible, stretchable coiled-sheet stent
CA2410948C (en) 2000-05-31 2012-07-17 Chiron Corporation Method for the purification of alphavirus replicon particles
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
EP1363663B1 (en) 2001-01-12 2011-03-02 Novartis Vaccines and Diagnostics, Inc. Nucleic acid mucosal immunization
EP2305299B1 (en) 2001-05-31 2017-03-01 GlaxoSmithKline Biologicals SA Chimeric alphavirus replicon particles
DE60233061D1 (de) 2001-09-06 2009-09-03 Alphavax Inc Alphavirus replikon-vektorsysteme
WO2004055161A2 (en) 2002-12-12 2004-07-01 The Board Of Regents Of The University Of Texas System Large scale production of packaged alphavirus replicons
NZ540657A (en) 2002-12-13 2006-09-29 Alphavax Inc High-yielding, GMP-compatible, commercially feasible process for producing highly purified alphavirus replicon particle (ARP) preparations for use in human and veterinary medicine
KR101454842B1 (ko) 2003-03-20 2014-11-04 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
AU2004257214B2 (en) 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines

Also Published As

Publication number Publication date
HK1082524A1 (zh) 2006-06-09
EP2290054A1 (en) 2011-03-02
EP1590451A2 (en) 2005-11-02
DK2290054T3 (en) 2017-07-03
CA2509979C (en) 2013-02-26
ES2890023T3 (es) 2022-01-17
ZA200505517B (en) 2006-03-29
EP1590451A4 (en) 2007-05-02
EP3246399A1 (en) 2017-11-22
IL169076A (en) 2010-05-31
CA2509979A1 (en) 2004-07-01
BRPI0317276B1 (pt) 2020-09-15
US20040166573A1 (en) 2004-08-26
AU2003297041B2 (en) 2009-02-26
DK1590451T3 (en) 2015-12-14
JP2012210224A (ja) 2012-11-01
EP2290054B1 (en) 2017-03-29
NZ540657A (en) 2006-09-29
JP5079981B2 (ja) 2012-11-21
JP5727420B2 (ja) 2015-06-03
BR0317276A (pt) 2005-11-08
AU2003297041A1 (en) 2004-07-09
WO2004055167A3 (en) 2005-01-13
CA2807515A1 (en) 2004-07-01
EP3246399B1 (en) 2021-07-07
EP1590451B1 (en) 2015-09-16
ES2630222T3 (es) 2017-08-18
CA2807515C (en) 2014-02-04
WO2004055167A2 (en) 2004-07-01
DK3246399T3 (da) 2021-10-04
JP2006509524A (ja) 2006-03-23
ES2552687T3 (es) 2015-12-01
US7078218B2 (en) 2006-07-18
BR122019005271B1 (pt) 2020-10-13

Similar Documents

Publication Publication Date Title
BRPI0317276B8 (pt) método para a preparação de partículas de replicon de alfavírus (arps)
Johnson et al. Paramyosin and Contraction of" Catch Muscles"
Schmidt et al. Calcium couples flagellar reversal to photostimulation in Chlamydomonas reinhardtii
BRPI0514694A (pt) produção de proteìna de fusão tnfr-ig
BR0215574B1 (pt) processo para recuperação de sal com baixo teor de sódio a partir de água-mãe das salinas.
AR019417A1 (es) Un proceso para la recuperacion directa de cloruro de litio a partir de una salmuera.
IL176481A0 (en) Simultaneous recovery of potassium chloride and kc1 enriched edible salt
NZ548724A (en) Process for the production of compositions containing ribonucleotides and their use as flavouring agents
RU2013144731A (ru) СПОСОБ ПОЛУЧЕНИЯ КОМПОЗИЦИИ ЧАСТИЦ, СОДЕРЖАЩЕЙ БЕЗВОДНУЮ КРИСТАЛЛИЧЕСКУЮ 2-О-α-D-ГЛЮКОЗИЛ-L-АСКОРБИНОВУЮ КИСЛОТУ
BRPI0507233A (pt) processo de produção de polipeptìdeo heterólogo em e.coli
Eveloff et al. Sodium-chloride transport in the medullary thick ascending limb of Henle's loop: evidence for a sodium-chloride cotransport system in plasma membrane vesicles
BRPI0400375B8 (pt) processo para remover vírus em soluções de fibrinogênio para aplicação terapêutica
ATE330909T1 (de) Entfernung von nitrat
Sorimachi Human and earth evolution through CO 2: Perspective for climate crisis
KR850007265A (ko) 염함량이 낮은 액상 수성 반응성 염료 조성물의 제조방법
CN109179455A (zh) 一种碳酸盐型盐湖卤水富集锂盐同时提取钾盐的方法
Arnason et al. An investigation of water splitting in the Kok scheme of photosynthetic oxygen evolution
Waldeck et al. Using triple oxygen isotopes to test Cretaceous/Cenozoic LIP activity as a driver of the marine sulfur cycle
DK0832845T3 (da) Anvendelse af hydratiserede salte for at forbedre ydelsen i produktionen af chlordioxid
GB1436509A (en) Method for producing s-adenosylmethionine or methylthioadenosine from yeast
Yates Microbial precipitation of calcium carbonate: a potential mechanism for lime-mud production
JP2009155269A5 (pt)
SU920080A1 (ru) Электролит дл получени пербората натри
JPS6210208B2 (pt)
Kim Development of bicarbonate-based microalgae cultivation system combined with electrochemical CO2 absorption process

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 7/02 , C12N 15/86

Ipc: C12N 7/02 (2006.01), C12N 15/86 (2006.01), A61K 39

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/12/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF